Allogeneic hematopoietic cell transplant (HCT) in patients (pts) >= 60 years of age with first relapsed or refractory acute myeloid leukemia (R/R AML) after treatment with vosaroxin plus cytarabine (vos/cyt) vs placebo plus cytarabine (pla/cyt): Results from VALOR.

Published

Conference Paper

Full Text

Duke Authors

Cited Authors

  • Schiller, GJ; Ritchie, EK; Sayar, H; Lancet, JE; Craig, MD; Vey, N; Strickland, SA; Erba, HP; Pigneux, A; Horst, H-A; Recher, C; Klimek, VM; Odenike, O; Craig, AR; Ward, R; Smith, J; Kantarjian, HM; Stuart, RK; Ravandi, F

Published Date

  • May 20, 2015

Published In

Volume / Issue

  • 33 / 15

Published By

Pages

  • 1

Electronic International Standard Serial Number (EISSN)

  • 1527-7755

International Standard Serial Number (ISSN)

  • 0732-183X

Conference Name

  • Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO) / Clinical Science Symposium on Predicting and Improving Adverse Outcomes in Older Adults with Cancer

Conference Location

  • Chicago, IL

Conference Start Date

  • May 29, 2015

Conference End Date

  • June 2, 2015